Methods of providing therapeutic effects using cyclosporin components
View Patent ↗Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
1. A topical ophthalmic emulsion for treating an eye of a human comprising cyclosporin A in an amount of about 0.05% by weight, polysorbate 80, acrylate/C10-30 alkyl acrylate cross-polymer, water, and castor oil in an amount of about 1.25% by weight;
wherein cyclosporin A is the only peptide present in the topical ophthalmic emulsion.
2. The topical ophthalmic emulsion of claim 1 , wherein the topical ophthalmic emulsion further comprises a tonicity agent or a demulcent component.
3. The topical ophthalmic emulsion of claim 2 , wherein the tonicity agent or the demulcent component is glycerine.
4. The topical ophthalmic emulsion of claim 1 , wherein the topical ophthalmic emulsion further comprises a buffer.
5. The topical ophthalmic emulsion of claim 4 , wherein the buffer is sodium hydroxide.
6. The topical ophthalmic emulsion of claim 1 , wherein the topical ophthalmic emulsion further comprises glycerine and a buffer.
7. The topical ophthalmic emulsion of claim 1 , wherein the topical ophthalmic emulsion comprises polysorbate 80 in an amount of about 1.0% by weight.
8. The topical ophthalmic emulsion of claim 1 , wherein the topical ophthalmic emulsion comprises acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight.
9. The topical ophthalmic emulsion of claim 1 , wherein the topical ophthalmic emulsion further comprises glycerine in an amount of about 2.2% by weight, water, and a buffer.
10. The topical ophthalmic emulsion of claim 9 , wherein the buffer is sodium hydroxide.
11. The topical ophthalmic emulsion of claim 1 , wherein, when the topical ophthalmic emulsion is administered to an eye of a human, the blood of the human has substantially no detectable concentration of cyclosporin A.
12. The topical ophthalmic emulsion of claim 6 , wherein the topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6.
13. A topical ophthalmic emulsion for treating an eye of a human, wherein the topical ophthalmic emulsion comprises:
cyclosporin A in an amount of about 0.05% by weight;
castor oil in an amount of about 1.25% by weight;
polysorbate 80 in an amount of about 1.0% by weight;
acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight;
a tonicity component or a demulcent component in an amount of about 2.2% by weight;
a buffer; and
water;
wherein the topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6 and wherein cyclosporin A is the only peptide present in the topical ophthalmic emulsion.
14. The topical ophthalmic emulsion of claim 13 , wherein the buffer is sodium hydroxide.
15. The topical ophthalmic emulsion of claim 13 , wherein the tonicity component or the demulcent component is glycerine.
16. The topical ophthalmic emulsion of claim 13 , wherein, when the topical ophthalmic emulsion is administered to an eye of a human, the blood of the human has substantially no detectable concentration of the cyclosporin A.
17. The topical ophthalmic emulsion of claim 13 , wherein the topical ophthalmic emulsion is effective in treating keratoconjunctivitis sicca.
18. A topical ophthalmic emulsion for treating an eye of a human, the topical ophthalmic emulsion comprising:
cyclosporin A in an amount of about 0.05% by weight;
castor oil in an amount of about 1.25% by weight;
polysorbate 80 in an amount of about 1.0% by weight;
acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight;
glycerine in an amount of about 2.2% by weight;
sodium hydroxide; and
water;
wherein cyclosporin A is the only peptide present in the topical ophthalmic emulsion.
19. The topical ophthalmic emulsion of claim 18 , wherein the topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6.
20. The topical ophthalmic emulsion of claim 1 , wherein the topical ophthalmic emulsion is therapeutically effective in treating dry eye.
21. The topical ophthalmic emulsion of claim 1 , wherein the topical ophthalmic emulsion is therapeutically effective in treating keratoconjunctivitis sicca.
22. The topical ophthalmic emulsion of claim 1 , wherein the topical ophthalmic emulsion is therapeutically effective in increasing tear production.
23. The topical ophthalmic emulsion of claim 13 , wherein the topical ophthalmic emulsion is therapeutically effective in treating dry eye.
24. The topical ophthalmic emulsion of claim 13 , wherein the topical ophthalmic emulsion is therapeutically effective in increasing tear production.
25. The topical ophthalmic emulsion of claim 18 , wherein the topical ophthalmic emulsion is therapeutically effective in treating dry eye.
26. The topical ophthalmic emulsion of claim 18 , wherein the topical ophthalmic emulsion is therapeutically effective in treating keratoconjunctivitis sicca.
27. The topical ophthalmic emulsion of claim 18 , wherein the topical ophthalmic emulsion is therapeutically effective in increasing tear production.